Most disease-causing variants fall not in genes but in the spaces between them, about which much less is known. This presents a major challenge for interpreting most of the disease-associated single nucleotide polymorphisms (SNPs) identified in a project like the UK Biobank. We plan to leverage our expertise in noncoding regions and the UK Biobank genetic and phenotypic variation to devise a new, multi-dimensional scoring scheme for predicting the impact of individual SNPs. The health benefits are potentially very large because it could allow the scientific community to understand the significance of many more disease-associated SNPs. Because of the relatively unexplored nature of the vast noncoding genome, we have no clear end date for the project.